Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®

Study sets new benchmark for Y-90 therapy in unresectable hepatocellular carcinoma

Apr. 13, 2026 at 1:14pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image revealing the detailed internal structure of a liver tumor, conveying the advanced medical technology used to precisely target and treat the cancer.Cutting-edge radioembolization technology targets liver tumors with precision and preserves organ function.Woburn Today

Sirtex Medical announced landmark 12-month results from the DOORwaY 90 study, the first pivotal, prospective, multicenter U.S. trial of Y-90 selective internal radiation therapy (SIRT) using partition dosimetry in patients with unresectable hepatocellular carcinoma (HCC). The study met its prespecified co-primary endpoints, demonstrating a 90% complete response rate and a best overall response rate of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment, resulting in 100% local tumor control.

Why it matters

These results raise the bar for what physicians should expect from Y-90 therapy, demonstrating that personalized dosimetry with SIR-Spheres can deliver outcomes that challenge conventional approaches and expand what's possible in liver-directed therapy for patients with unresectable HCC.

The details

The DOORwaY 90 study used partition dosimetry, a personalized approach to determine the optimal radiation dose for each patient. This allowed the treatment to achieve aggressive tumor response without compromising hepatic reserve, as over 95% of patients maintained stable liver function at 12 months.

  • The DOORwaY 90 study results were presented at the Society of Interventional Radiology (SIR) Annual Meeting in Toronto, Canada on April 13, 2026.

The players

Sirtex Medical

A leading manufacturer of interventional oncology and embolization solutions.

Dr. Armeen Mahvash

Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 study.

Matt Schmidt

CEO of Sirtex Medical.

Got photos? Submit your photos here. ›

What they’re saying

“These 12-month results demonstrate the consistency of response achievable with personalized dosimetry. The high complete response rates, durability and preservation of liver function observed in this study give physicians increased confidence in using radioembolization as a definitive, liver-directed treatment option.”

— Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 study

“These results raise the bar for what physicians should expect from Y-90 therapy. With the overall response rate of 99% and 100% tumor control, DOORwaY 90 demonstrates that personalized dosimetry with SIR-Spheres can deliver outcomes that challenge conventional approaches and expand what's possible in liver-directed therapy for patients with unresectable HCC.”

— Matt Schmidt, CEO of Sirtex Medical

What’s next

Sirtex Medical plans to continue studying the use of SIR-Spheres Y-90 resin microspheres and personalized dosimetry approaches in patients with unresectable hepatocellular carcinoma.

The takeaway

The DOORwaY 90 study results set a new benchmark for Y-90 therapy, demonstrating that personalized dosimetry can achieve unprecedented tumor response rates while preserving liver function in patients with unresectable HCC. These findings could lead to increased adoption of radioembolization as a definitive, liver-directed treatment option.